LevelsRx says it raised $20M and plans to expand nationwide (with Louisiana excluded for now)
LevelsRx, an online clinician-guided weight management provider, says it has secured $20 million in new funding and is planning a broader U.S. rollout that would make the service available in every U.S. state except Louisiana.
The company shared the update directly with Howset. LevelsRx did not publicly disclose additional deal terms at the time of publication, including a full investor list, valuation, or the specific breakdown of how the capital will be allocated.
What LevelsRx does (and why expansion matters)
LevelsRx positions itself as a fully online weight management program that connects patients with licensed providers and ships medications from licensed pharmacies, with ongoing check-ins and support through its platform. On its website, the company describes a workflow that starts with an online intake, followed by provider evaluation, and then medication shipment, with continued monitoring and messaging support over time.
In the current GLP-1 telehealth market, “nationwide” claims can be messy in practice because telehealth availability often depends on state-by-state licensing and operational coverage. LevelsRx itself notes that some steps in the care flow can vary “depending on the state,” which is one reason expansions tend to roll out in phases rather than flipping on all locations at once.
“All states except Louisiana” — what that likely means in practice
LevelsRx’s plan, as described to Howset, is to offer services across the U.S. while excluding Louisiana in the near term. The company did not provide a public-facing explanation for the Louisiana exception, and it’s worth flagging that state availability can change over time as licensing, staffing, pharmacy logistics, and regulatory requirements evolve.
For readers, the practical takeaway is simple: even if a provider says it is “nationwide,” availability is still something you should confirm directly inside the signup flow or with support—especially for telehealth programs that involve prescription fulfillment.
Important context: GLP-1 telehealth is under a brighter spotlight
The broader GLP-1 ecosystem has been moving quickly, and scrutiny has increased—particularly around marketing practices, pharmacy fulfillment, and compounded versions of GLP-1 medications. Major manufacturers have also taken legal action against some telehealth companies tied to off-brand or compounded GLP-1 offerings, adding another layer of attention to the category.
LevelsRx lists both branded GLP-1 medications and compounded options on its site, and it includes compliance-style language noting that medications are issued only if clinically appropriate after a provider evaluation.
Privacy and patient data
Because GLP-1 programs typically involve health histories, ongoing monitoring, and prescription workflows, privacy practices are becoming a bigger part of how consumers evaluate providers.
LevelsRx publishes a HIPAA-oriented Notice of Privacy Practices that describes an “Affiliated Covered Entity (ACE)” structure and names participating entities, along with a plain-language list of patient rights (access, corrections, accounting of disclosures, and complaint pathways).
What’s next
LevelsRx says the fresh funding and expanded footprint are intended to support broader access to its program and operations. The company has not yet published a detailed public announcement with additional financing specifics, so more clarity may emerge if it later posts a release, investor statement, or updated materials.
For now, the headline is straightforward: LevelsRx says it has raised $20 million and is moving toward broad U.S. availability, with Louisiana excluded in the initial expansion plan.
Note for readers: This article is about a company update and market expansion. It is not medical advice. GLP-1 medications are prescription drugs and aren’t appropriate for everyone. Anyone considering GLP-1 treatment—or starting a new exercise program—should speak with a licensed healthcare professional.
